Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Remicade Biosimilar Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The remicade biosimilar market size has seen remarkable growth in recent years. It is forecast to increase from $4.89 billion in 2025 to $5.97 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.2%. The expansion witnessed in prior periods can be attributed to the considerable expense of branded biologics, the expiration of remicade’s patent, an increasing occurrence of autoimmune diseases, government assistance for biosimilar approvals, and hospital-led bulk purchasing strategies.
The remicade biosimilar market size is set for significant expansion over the coming years. It is projected to reach $13.31 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 22.2%. This anticipated growth in the forecast period is fueled by a rising demand for affordable biologic treatments, the expansion of biosimilar development pipelines, increasing healthcare expenditure in emerging economies, growing acceptance among both medical professionals and patients, and favorable reimbursement policies. Key trends for the forecast period include a wider adoption of cost-effective biosimilars, enhanced prescriber confidence in infliximab biosimilars, an expansion of their indications across autoimmune disorders, competitive pricing models alongside tender-based procurement, and deeper market penetration in developing healthcare markets.
Get A Free Sample Report With In-Depth Market Insights:
Remicade Biosimilar Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of autoimmune conditions is anticipated to drive expansion in the remicade biosimilar market. These conditions involve the immune system erroneously targeting and harming the body’s own tissues and organs. Remicade biosimilars serve as a vital therapeutic choice for managing autoimmune diseases, effectively controlling symptoms and diminishing related inflammation. For example, data from February 2024 by Arthritis Australia, an advocacy group for individuals with arthritis and musculoskeletal issues, indicates that roughly 562,378 Australians are projected to have rheumatoid arthritis (RA) by 2025, making up 14% of the overall arthritis demographic. This figure for RA sufferers is forecast to climb by 33% to about 748,721 by 2040. Consequently, the increasing prevalence of autoimmune diseases is a key factor boosting the remicade biosimilar market.
Remicade Biosimilar Market Segment Analysis: What Are The Core Market Categories?
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Remicade Biosimilar Market Trends Redefining Industry Growth
Companies operating in the remicade biosimilar market are primarily focused on developing innovative solutions, such as subcutaneous formulations, to gain a competitive advantage. These subcutaneous formulations of Remicade offer an alternative administration method for treating autoimmune diseases, facilitating self-administration and potentially enhancing patient adherence to therapy. For instance, in March 2024, Celltrion, a South Korea-based biopharmaceutical company, launched Zymfentra, a biosimilar to Remicade (infliximab) for $6,181.08 for two doses over four weeks, which received FDA approval as the first subcutaneous infliximab formulation for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Eligible commercially insured patients can receive copay assistance of $5 per month, while uninsured or underinsured patients may obtain Zymfentra at no cost.
Remicade Biosimilar Market Top Companies Driving Competitive Growth
Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A
View The Full Remicade Biosimilar Market Report:
Remicade Biosimilar Market Geographic Distribution And Regional Opportunities
Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model